Corcept Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Corcept Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Corcept Therapeutics Inc Strategy Report
- Understand Corcept Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Corcept Therapeutics Inc (Corcept) discovers, develops, and commercializes innovative medicines for the treatmentof psychiatric, oncologic, and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome;miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder, and post-traumatic stress disorder among others. Corcept is headquartered in Menlo Park, California, the US.
Headquarters
United States of America
Address
149 Commonwealth Dr, Menlo Park, California, 94025
Website
www.corcept.com
Telephone
1 650 3273270
No of Employees
352
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CORT (NASD)
Revenue (2022)
$482.4M
20%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
4.7%
(2022 vs 2021)
Market Cap*
$2.4B
Net Profit Margin (2022)
XYZ
-12.8%
(2022 vs 2021)
* As of and is in US$
Corcept Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Korlym | - |
| Pipeline: | Corcept |
| Relacorilant- Endogenous Cushing Syndrome; Hypercortisolism associated with Cortisol-Secreting Adrenal Adenoma or Hyperplasia | Korlym |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Corcept Therapeutics Inc | Recordati SpA | Acadia Pharmaceuticals Inc | Amicus Therapeutics Inc | MannKind Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | Italy | United States of America | United States of America | United States of America |
| City | Menlo Park | Milano | San Diego | Philadelphia | Danbury |
| State/Province | California | - | California | Pennsylvania | Connecticut |
| No. of Employees | 352 | 4,455 | 597 | 517 | 414 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James N. Wilson | Chairman | Executive Board | 1999 | 77 |
| Joseph K. Belanoff, M.D. | Director; President; Chief Executive Officer | Executive Board | 2014 | 63 |
| Atabak Mokari | Chief Financial Officer | Senior Management | 2021 | - |
| J.D. Lyon | Chief Accounting Officer | Senior Management | 2020 | - |
| Hazel Hunt Ph.D. | Chief Scientific Officer | Senior Management | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward